Figure 3.

Effects of CB₂R agonist treatment on macrophage infiltration into the DRG of LP-BM5-infected animals. After LP-BM5 infection, synthetic CB₂R ligands were injected (5 mg/kg, i.p.) twice/wk starting at 5 or 6 wk (HU308) p.i. At 12 wk p.i., DRG were dissected and mononuclear cells from six ganglia (L3–L5) per mouse were isolated using nonenzymatic dissociation. Isolated cells were then stained using Abs specific for CD45, CD11b, and MHCII for analysis by flow cytometry. (a) Representative contour plots show percentages of macrophages (i.e., CD45^hiCD11b^hi) expressing MHCII within uninfected (UI), infected (IF), and infected (IF + indicated CB₂R ligand), agonist-treated DRG. (b) Numbers of macrophages infiltrating DRG of animals belonging to the indicated treatment groups. (c) Frequency of macrophages expressing MHCII within DRG of animals belonging to the indicated groups. Pooled data present absolute numbers (mean ± SE) from two independent experiments using 4–6 animals/group. ^∗p < 0.05; ^∗∗p < 0.01.